0
     

Report Added
Report already added
Human Genetics Market—Forecast till 2027

Human Genetics Market—Forecast till 2027

Human Genetics Market—Forecast till 2027

Market Snapshot
The global human genetics market is anticipated to register a substantial market expansion at a notable CAGR of 17.76% during the review period to surpass USD 1,12,536.54 million by 2027.
Human genetics is the investigation of the conveyance of qualities through ages. Adjustment in the genome might bring about change, a little piece of which might prompt the infection aggregate. Hereditary sicknesses can be monogenic, multifactorial, and chromosomal are passed down from the guardians to the descendants by various legacy designs, for example, X-connected latent, autosomal passive, and autosomal prevailing.

Developing predominance of epilepsy among the geriatric populace go about as significant driver in the worldwide human genetics market during 2021-2027. Nonetheless, significant expense of hereditary testing impedes the development of the worldwide human genetics market during the conjecture time frame. The developing utilization of hereditary information across medical services and innovative progression in hereditary testing is relied upon to set out a freedom in the worldwide human genetics market.

Market Segmentation
Global Human Genetics Market has been segregated based on Application, and test.
Based on application the global market has been classified into Wellness & E-Commerce, Preventive Medicine, Diagnostic & Treatment, Oncology, Cardiology, Assisted Reproduction, Neurology, Gynaecology, and others.

The neurology segment is further sub-divided into Neuropediatric and Others. Based on the Test segment, the Global Human Genetics Market has been categorized into NIPT, Carrier Testing, Pharmacogenomic Testing, Thrombophilia Testing, Septin 9 Biomarker Testing, NGS, and others.

Regional Analysis
Geographically, the global human genetics market, has been studied across the US, Canada, UK, Germany, Spain, Japan, Others.
The human genetics market in the US benefits from a high medical care use, expanding interest for hereditary testing by the populace, and high open mindfulness with respect to early discovery of infections and preventive consideration. Also, the accessibility of repayments in the US for hereditary tests further develops market development in the country.

Genomic wellbeing information in the UK is created in three significant regions, including enormous scope research programs, the medical services framework, and buying of direct-to-purchaser hereditary testing. Additionally, the ascent in the number of drives embraced by people in general as well as private associations is further supporting the market development.

In Germany, the rising commonness of hereditary issues, disease, expanding mindfulness and acknowledgment regarding customized meds, and developing spotlight on R&D exercises add to the nation's development. Also, the public authority is executing various good and cooperative approaches to consolidate hereditary testing into the medical care framework and give protection repayments to residents, which, thusly, is driving the market development.
DNA testing at home in Japan is acquiring a foothold among the older populace looking for answers in regard to their wellbeing and illness chances.

Major Players
The Key Companies operating in the global human genetics market includes GENinCode (UK), Atrys Health (Spain), Genyca (Spain), Igenomix (India), Genologica (Spain), Myriad Genetics (US), NIMGenetics (Spain), Sistemas Genómicos (Spain), FullGenomics (Spain), Synlab Group (Germany), Eurofins Megalab S.A (Spain), Biomarker Technology (US), Echevarne Laboratory (Spain), Elabscience Biotechnology Inc (US), and Bode Technology Group Inc (US).

COVID 19 Impacts
We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.

TABLE OF CONTENTS
1 EXECUTIVE SUMMARY 14
2 MARKET INTRODUCTION 15
2.1 DEFINITION 15
2.2 SCOPE OF THE STUDY 15
2.3 RESEARCH OBJECTIVE 15
2.4 MARKET STRUCTURE 15
2.5 ASSUMPTIONS & LIMITATIONS 16
3 RESEARCH METHODOLOGY 17
3.1 DATA MINING 17
3.2 SECONDARY RESEARCH 18
3.3 PRIMARY RESEARCH 19
3.4 BREAKDOWN OF PRIMARY RESPONDENTS 20
3.5 FORECASTING TECHNIQUES 21
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 22
3.6.1 BOTTOM-UP APPROACH 23
3.6.2 TOP-DOWN APPROACH 23
3.7 DATA TRIANGULATION 24
3.8 VALIDATION 24
4 MARKET DYNAMICS 25
4.1 OVERVIEW 25
4.2 DRIVERS 26
4.2.1 GROWING ADOPTION OF GENETIC TESTING 26
4.2.2 INCREASING INCIDENCES OF GENETIC DISEASES AND CANCER 26
4.3 RESTRAINTS 27
4.3.1 HIGH COST OF GENETIC TESTING 27
4.3.2 SHORTAGE OF SKILLED AND EXPERIENCED GENETIC COUNSELORS 27
4.4 OPPORTUNITY 28
4.4.1 GROWING USE OF GENETIC DATA ACROSS HEALTHCARE AND TECHNOLOGICAL ADVANCEMENTS IN GENETIC TESTING 28
5 MARKET FACTOR ANALYSIS 29
5.1 VALUE CHAIN ANALYSIS 29
5.1.1 R&D 30
5.1.2 MANUFACTURING 30
5.1.3 DISTRIBUTION & SALES 30
5.1.4 POST-SALES MONITORING 30
5.2 PORTER'S FIVE FORCES MODEL 31
5.2.1 THREAT OF NEW ENTRANTS 31
5.2.2 BARGAINING POWER OF SUPPLIERS 32
5.2.3 THREAT OF SUBSTITUTES 32
5.2.4 BARGAINING POWER OF BUYERS 32
5.2.5 INTENSITY OF RIVALRY 32
5.3 IMPACT OF COVID-19 ON THE GLOBAL HUMAN GENETICS MARKET 32
5.3.1 IMPACT ON SUPPLY CHAIN 32
5.3.2 IMPACT ON PATIENTS SUFFERING FROM GENETIC DISEASES 33
5.3.3 IMPACT ON KEY PLAYERS 33
6 GLOBAL HUMAN GENETICS MARKET, BY APPLICATION 34
6.1 OVERVIEW 34
6.2 WELLNESS & E-COMMERCE 35
6.3 PREVENTIVE MEDICINE 35
6.4 DIAGNOSTIC & TREATMENT 36
7 GLOBAL HUMAN GENETICS MARKET, BY TEST 42
7.1 OVERVIEW 42
7.2 NIPT 43
7.3 CARRIER TESTING 44
7.4 PHARMACOGENOMIC TESTING 45
7.5 KARYOTYPE TESTING 46
7.6 THROMBOPHILIA TESTING 47
7.7 SEPTIN 9 BIOMARKER TESTING 48
7.8 NGS 49
7.9 OTHERS 51
8 GLOBAL HUMAN GENETICS MARKET, BY COUNTRY 52
8.1 OVERVIEW 52
8.1.1 US 53
8.1.2 CANADA 55
8.1.3 UK 57
8.1.4 GERMANY 59
8.1.5 SPAIN 61
8.1.6 JAPAN 63
8.1.7 OTHERS 65
9 COMPETITIVE LANDSCAPE 67
9.1 OVERVIEW 67
9.2 COMPETITIVE BENCHMARKING 68
9.3 MAJOR GROWTH STRATEGY IN THE HUMAN GENETICS MARKET 69
9.4 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE HUMAN GENETICS MARKET 70
9.5 KEY DEVELOPMENT ANALYSIS 71
9.6 KEY DEVELOPMENTS & GROWTH STRATEGIES 71
9.6.1 PRODUCT LAUNCH/PRODUCT APPROVAL 71
9.6.2 MERGER &ACQUISITION 71
9.6.3 EXPANSION 72
9.7 FINANCIAL MATRIX 72
9.7.1 SALES (USD MILLION), 2020 72
10 COMPANY PROFILES 73
10.1 MYRIAD GENETICS, INC. 73
10.1.1 COMPANY OVERVIEW 73
10.1.2 FINANCIAL OVERVIEW 74
10.1.3 PRODUCT/SERVICE OFFERED 75
10.1.4 KEY DEVELOPMENTS 75
10.1.5 SWOT ANALYSIS 76
10.1.6 KEY STRATEGIES 76
10.2 SYNLAB GROUP 77
10.2.1 COMPANY OVERVIEW 77
10.2.2 FINANCIAL OVERVIEW 77
10.2.3 PRODUCT/SERVICE OFFERED 78
10.2.4 KEY DEVELOPMENTS 78
10.2.5 SWOT ANALYSIS 79
10.2.6 KEY STRATEGIES 79
10.3 EUROFINS MEGALAB S.A. 80
10.3.1 COMPANY OVERVIEWS 80
10.3.2 FINANCIAL OVERVIEW 80
10.3.3 PRODUCT/SERVICE OFFERED 81
10.3.4 KEY DEVELOPMENTS 81
10.3.5 SWOT ANALYSIS 81
10.3.6 KEY STRATEGIES 82
10.4 BIOMARKER TECHNOLOGIES. 83
10.4.1 COMPANY OVERVIEW 83
10.4.2 FINANCIAL OVERVIEW 83
10.4.3 PRODUCT/SERVICE OFFERED 83
10.4.4 KEY DEVELOPMENTS 83
10.4.5 SWOT ANALYSIS 84
10.4.6 KEY STRATEGIES 84
10.5 ECHEVARNE LABORATORY 85
10.5.1 COMPANY OVERVIEW 85
10.5.2 FINANCIAL OVERVIEW 85
10.5.3 PRODUCT/SERVICE OFFERED 85
10.5.4 KEY DEVELOPMENTS 85
10.5.5 SWOT ANALYSIS 86
10.5.6 KEY STRATEGIES 86
10.6 ELABSCIENCE BIOTECHNOLOGY INC. 87
10.6.1 COMPANY OVERVIEW 87
10.6.2 FINANCIAL OVERVIEW 87
10.6.3 PRODUCT/SERVICE OFFERED 87
10.6.4 KEY DEVELOPMENTS 87
10.6.5 SWOT ANALYSIS 88
10.6.6 KEY STRATEGIES 88
10.7 NIMGENETICS 89
10.7.1 COMPANY OVERVIEW 89
10.7.2 FINANCIAL OVERVIEW 89
10.7.3 PRODUCT/SERVICE OFFERED 89
10.7.4 KEY DEVELOPMENTS 90
10.7.5 SWOT ANALYSIS 90
10.7.6 KEY STRATEGIES 90
10.8 SISTEMAS GENÓMICOS 91
10.8.1 COMPANY OVERVIEW 91
10.8.2 FINANCIAL OVERVIEW 91
10.8.3 PRODUCTS/SERVICES OFFERED 91
10.8.4 KEY DEVELOPMENTS 91
10.8.5 SWOT ANALYSIS 92
10.8.6 KEY STRATEGIES 92
10.9 FULLGENOMICS 93
10.9.1 COMPANY OVERVIEW 93
10.9.2 FINANCIAL OVERVIEW 93
10.9.3 PRODUCTS/SERVICES OFFERED 93
10.9.4 KEY DEVELOPMENTS 93
10.9.5 SWOT ANALYSIS 94
10.9.6 KEY STRATEGIES 94
10.10 GENINCODE 95
10.10.1 COMPANY OVERVIEW 95
10.10.2 FINANCIAL OVERVIEW 95
10.10.3 PRODUCTS/SERVICES OFFERED 95
10.10.4 KEY DEVELOPMENTS 95
10.10.5 SWOT ANALYSIS 96
10.10.6 KEY STRATEGIES 96
10.11 ATRYS HEALTH 97
10.11.1 COMPANY OVERVIEW 97
10.11.2 FINANCIAL OVERVIEW 97
10.11.3 PRODUCTS/SERVICES OFFERED 97
10.11.4 KEY DEVELOPMENTS 97
10.11.5 SWOT ANALYSIS 98
10.11.6 KEY STRATEGIES 98
10.12 GENYCA 99
10.12.1 COMPANY OVERVIEW 99
10.12.2 FINANCIAL OVERVIEW 99
10.12.3 PRODUCTS/SERVICES OFFERED 99
10.12.4 KEY DEVELOPMENTS 99
10.12.5 SWOT ANALYSIS 100
10.12.6 KEY STRATEGIES 100
10.13 IGENOMIX 101
10.13.1 COMPANY OVERVIEW 101
10.13.2 FINANCIAL OVERVIEW 101
10.13.3 PRODUCTS/SERVICES OFFERED 101
10.13.4 KEY DEVELOPMENTS 101
10.13.5 SWOT ANALYSIS 102
10.13.6 KEY STRATEGIES 102
10.14 GENOLÓGICA 103
10.14.1 COMPANY OVERVIEW 103
10.14.2 FINANCIAL OVERVIEW 103
10.14.3 PRODUCTS/SERVICES OFFERED 103
10.14.4 KEY DEVELOPMENTS 103
10.14.5 SWOT ANALYSIS 104
10.14.6 KEY STRATEGIES 104
10.15 BODE CELLMARK FORENSICS, INC. 105
10.15.1 COMPANY OVERVIEW 105
10.15.2 FINANCIAL OVERVIEW 105
10.15.3 PRODUCTS/SERVICES OFFERED 105
10.15.4 KEY DEVELOPMENTS 105
10.15.5 SWOT ANALYSIS 106
10.15.6 KEY STRATEGIES 106
11 APPENDIX 107
11.1 REFERENCES 107
11.2 RELATED REPORTS 107

LIST OF TABLES
TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS 16
TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS 19
TABLE 3 GLOBAL HUMAN GENETICS MARKET, BY APPLICATION, 2018–2027 (USD MILLION) 34
TABLE 4 GLOBAL HUMAN GENETICS MARKET FOR WELLNESS & E-COMMERCE, BY COUNTRY, 2018–2027 (USD MILLION) 35
TABLE 5 GLOBAL HUMAN GENETICS MARKET FOR PREVENTIVE MEDICINE, BY COUNTRY, 2018–2027 (USD MILLION) 36
TABLE 6 GLOBAL HUMAN GENETICS MARKET FOR DIAGNOSTIC & TREATMENT, BY COUNTRY, 2018–2027 (USD MILLION) 37
TABLE 7 GLOBAL HUMAN GENETICS MARKET FOR APPLICATION, BY DIAGNOSTIC & TREATMENT, BY TYPE, 2018–2027 (USD MILLION) 37
TABLE 8 GLOBAL HUMAN GENETICS MARKET FOR ONCOLOGY, BY COUNTRY, 2018–2027 (USD MILLION) 38
TABLE 9 GLOBAL HUMAN GENETICS MARKET FOR CARDIOLOGY, BY COUNTRY, 2018–2027 (USD MILLION) 38
TABLE 10 GLOBAL HUMAN GENETICS MARKET FOR NEUROLOGY, BY COUNTRY, 2018–2027 (USD MILLION) 39
TABLE 11 GLOBAL HUMAN GENETICS MARKET FOR ASSISTED REPRODUCTION, BY COUNTRY, 2018–2027 (USD MILLION) 39
TABLE 12 GLOBAL HUMAN GENETICS MARKET FOR GYNECOLOGY, BY COUNTRY, 2018–2027 (USD MILLION) 40
TABLE 13 GLOBAL HUMAN GENETICS MARKET FOR OTHERS, BY COUNTRY, 2018–2027 (USD MILLION) 40
TABLE 14 GLOBAL HUMAN GENETICS MARKET FOR DIAGNOSTIC & TREATMENT, BY NEUROLOGY, BY TYPE, 2018–2027 (USD MILLION) 40
TABLE 15 GLOBAL HUMAN GENETICS MARKET FOR NEUROPEDIATRIC, BY COUNTRY, 2018–2027 (USD MILLION) 41
TABLE 16 GLOBAL HUMAN GENETICS MARKET FOR OTHERS, BY COUNTRY, 2018–2027 (USD MILLION) 41
TABLE 17 GLOBAL HUMAN GENETICS MARKET, BY TEST, 2018–2027 (USD MILLION) 43
TABLE 18 GLOBAL HUMAN GENETICS MARKET FOR NIPT, BY COUNTRY, 2018–2027 (USD MILLION) 44
TABLE 19 GLOBAL HUMAN GENETICS MARKET FOR CARRIER TESTING, BY COUNTRY, 2018–2027 (USD MILLION) 45
TABLE 20 GLOBAL HUMAN GENETICS MARKET FOR PHARMACOGENOMIC TESTING, BY COUNTRY, 2018–2027 (USD MILLION) 46
TABLE 21 GLOBAL HUMAN GENETICS MARKET FOR KARYOTYPE TESTING, BY COUNTRY, 2018–2027 (USD MILLION) 47
TABLE 22 GLOBAL HUMAN GENETICS MARKET FOR THROMBOPHILIA TESTING, BY COUNTRY, 2018–2027 (USD MILLION) 48
TABLE 23 GLOBAL HUMAN GENETICS MARKET FOR SEPTIN 9 BIOMARKER TESTING, BY COUNTRY, 2018–2027 (USD MILLION) 48
TABLE 24 GLOBAL HUMAN GENETICS MARKET FOR NGS, BY COUNTRY, 2018–2027 (USD MILLION) 49
TABLE 25 GLOBAL HUMAN GENETICS MARKET FOR NGS, BY TYPE, 2018–2027 (USD MILLION) 49
TABLE 26 GLOBAL HUMAN GENETICS MARKET FOR ONCOLOGY, BY COUNTRY, 2018–2027 (USD MILLION) 49
TABLE 27 GLOBAL HUMAN GENETICS MARKET FOR CARDIOLOGY, BY COUNTRY, 2018–2027 (USD MILLION) 50
TABLE 28 GLOBAL HUMAN GENETICS MARKET FOR OTHERS, BY COUNTRY, 2018–2027 (USD MILLION) 51
TABLE 29 GLOBAL HUMAN GENETICS MARKET FOR OTHERS, BY COUNTRY, 2018–2027 (USD MILLION) 51
TABLE 30 GLOBAL HUMAN GENETICS MARKET, BY COUNTRY, 2018–2027 (USD MILLION) 52
TABLE 31 US: HUMAN GENETICS MARKET, BY APPLICATION, 2018–2027 (USD MILLION) 53
TABLE 32 US: HUMAN GENETICS MARKET FOR DIAGNOSTIC & TREATMENT, BY TYPE, 2018–2027 (USD MILLION) 53
TABLE 33 US: HUMAN GENETICS MARKET FOR NEUROLOGY, BY TYPE, 2018–2027 (USD MILLION) 54
TABLE 34 US: HUMAN GENETICS MARKET, BY TEST, 2018–2027 (USD MILLION) 54
TABLE 35 US: HUMAN GENETICS MARKET FOR BY NGS, BY TYPE, 2018–2027 (USD MILLION) 54
TABLE 36 CANADA: HUMAN GENETICS MARKET, BY APPLICATION, 2018–2027 (USD MILLION) 55
TABLE 37 CANADA: HUMAN GENETICS MARKET FOR DIAGNOSTIC & TREATMENT, BY TYPE, 2018–2027 (USD MILLION) 55
TABLE 38 CANADA: HUMAN GENETICS MARKET FOR NEUROLOGY, BY TYPE, 2018–2027 (USD MILLION) 56
TABLE 39 CANADA: HUMAN GENETICS MARKET, BY TEST, 2018–2027 (USD MILLION) 56
TABLE 40 CANADA: HUMAN GENETICS MARKET FOR NGS, BY TYPE, 2018–2027 (USD MILLION) 56
TABLE 41 UK: HUMAN GENETICS MARKET, BY APPLICATION, 2018–2027 (USD MILLION) 57
TABLE 42 UK: HUMAN GENETICS MARKET FOR BY DIAGNOSTIC & TREATMENT, BY TYPE, 2018–2027 (USD MILLION) 57
TABLE 43 UK: HUMAN GENETICS MARKET FOR NEUROLOGY, BY TYPE, 2018–2027 (USD MILLION) 58
TABLE 44 UK: HUMAN GENETICS MARKET, BY TEST, 2018–2027 (USD MILLION) 58
TABLE 45 UK: HUMAN GENETICS MARKET FOR NGS, BY TYPE, 2018–2027 (USD MILLION) 58
TABLE 46 GERMANY: HUMAN GENETICS MARKET, BY APPLICATION, 2018–2027 (USD MILLION) 59
TABLE 47 GERMANY: HUMAN GENETICS MARKET FOR DIAGNOSTIC & TREATMENT, BY TYPE, 2018–2027 (USD MILLION) 59
TABLE 48 GERMANY: HUMAN GENETICS MARKET FOR NEUROLOGY, BY TYPE, 2018–2027 (USD MILLION) 60
TABLE 49 GERMANY: HUMAN GENETICS MARKET, BY TEST, 2018–2027 (USD MILLION) 60
TABLE 50 GERMANY: HUMAN GENETICS MARKET FOR NGS, BY TYPE, 2018–2027 (USD MILLION) 60
TABLE 51 SPAIN: HUMAN GENETICS MARKET, BY APPLICATION, 2018–2027 (USD MILLION) 61
TABLE 52 SPAIN: HUMAN GENETICS MARKET FOR DIAGNOSTIC & TREATMENT, FOR TYPE, 2018–2027 (USD MILLION) 61
TABLE 53 SPAIN: HUMAN GENETICS MARKET FOR NEUROLOGY, BY TYPE, 2018–2027 (USD MILLION) 62
TABLE 54 SPAIN: HUMAN GENETICS MARKET, BY TEST, 2018–2027 (USD MILLION) 62
TABLE 55 SPAIN: HUMAN GENETICS MARKET FOR NGS, BY TYPE, 2018–2027 (USD MILLION) 62
TABLE 56 JAPAN: HUMAN GENETICS MARKET, BY APPLICATION, 2018–2027 (USD MILLION) 63
TABLE 57 JAPAN: HUMAN GENETICS MARKET FOR DIAGNOSTIC & TREATMENT, BY TYPE, 2018–2027 (USD MILLION) 63
TABLE 58 JAPAN: HUMAN GENETICS MARKET FOR NEUROLOGY, BY TYPE, 2018–2027 (USD MILLION) 64
TABLE 59 JAPAN: HUMAN GENETICS MARKET, BY TEST, 2018–2027 (USD MILLION) 64
TABLE 60 JAPAN: HUMAN GENETICS MARKET FOR NGS, BY TYPE, 2018–2027 (USD MILLION) 64
TABLE 61 OTHERS: HUMAN GENETICS MARKET, BY APPLICATION, 2018–2027 (USD MILLION) 65
TABLE 62 OTHERS: HUMAN GENETICS MARKET FOR DIAGNOSTIC & TREATMENT, BY TYPE, 2018–2027 (USD MILLION) 65
TABLE 63 OTHERS: HUMAN GENETICS MARKET FOR NEUROLOGY, BY TYPE, 2018–2027 (USD MILLION) 66
TABLE 64 OTHERS: HUMAN GENETICS MARKET, BY TEST, 2018–2027 (USD MILLION) 66
TABLE 65 OTHERS: HUMAN GENETICS MARKET FOR NGS, BY TYPE, 2018–2027 (USD MILLION) 66
TABLE 66 MAJOR PLAYERS IN THE HUMAN GENETICS MARKET 67
TABLE 67 MOST ACTIVE PLAYER IN THE HUMAN GENETICS MARKET 70
TABLE 68 PRODUCT LAUNCH/PRODUCT APPROVAL 71
TABLE 69 MERGER & ACQUISITION 71
TABLE 70 EXPANSION 72
TABLE 71 MYRIAD GENETICS INC.: PRODUCT/SERVICE OFFERED 75
TABLE 72 MYRIAD GENETICS INC.: KEY DEVELOPMENTS 75
TABLE 73 SYNLAB GROUP: PRODUCT/SERVICE OFFERED 78
TABLE 74 SYNLAB GROUP: KEY DEVELOPMENTS 78
TABLE 75 EUROFINS MEGALAB S.A: PRODUCT/SERVICE OFFERED 81
TABLE 76 BIOMARKER TECHNOLOGIES: PRODUCT/SERVICE OFFERED 83
TABLE 77 ECHEVARNE LABORATORY: PRODUCT /SERVICE OFFERED 85
TABLE 78 ELABSCIENCE BIOTECHNOLOGY INC.: PRODUCT/SERVICE OFFERED 87
TABLE 79 NIMGENETICS: PRODUCT/SERVICE OFFERED 89
TABLE 80 SISTEMAS GENÓMICOS: PRODUCTS OFFERED 91
TABLE 81 FULLGENOMICS: PRODUCTS/SERVICES OFFERED 93
TABLE 82 GENINCODE: PRODUCTS/SERVICES OFFERED 95
TABLE 83 GENINCODE: KEY DEVELOPMENTS 95
TABLE 84 ATRYS HEALTH: PRODUCTS/SERVICES OFFERED 97
TABLE 85 GENYCA: PRODUCTS/SERVICES OFFERED 99
TABLE 86 IGENOMIX: PRODUCTS/SERVICES OFFERED 101
TABLE 87 IGENOMIX: KEY DEVELOPMENTS 101
TABLE 88 GENOLOGICA: PRODUCTS/SERVICES OFFERED 103
TABLE 89 BODE CELLMARK FORENSICS, INC.: PRODUCTS/SERVICES OFFERED 105

Report Title: Human Genetics Market—Forecast till 2027


Your Details
Valid Invalid number

SELECT A FORMAT

ADD TO CART BUY NOW

Related Report

Dental Imaging Systems: Global Markets

Dental Imaging Systems: Global Markets

Telecom operators’ strategies in the health market

Telecom operators’ strategies in the health market

China Bispecific Antibody Market Opportunity & Clinical Trials Insight 2028

China Bispecific Antibody Market Opportunity & Clinical Trials Insight 2028

2022 Vietnam Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 Vietnam Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 Venezuela Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 Venezuela Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 Uruguay Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 Uruguay Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline